FDA Seeks Input on Remote Robotic Surgery Devices
The agency's discussion paper addresses robotic medical devices with autonomous or remote teleoperation capabilities, with comments due Jan. 5.
Updated on Nov. 9, 2026 in Robotics

Live Poll
Would you trust a robot to perform surgery on you while the surgeon is far away?
The FDA issued a discussion paper on robotic medical devices with autonomous or remote teleoperation capabilities and is requesting feedback on their benefits and risks. Comments on the paper are due by Jan. 5, and a public workshop on the topics is scheduled for Dec. 2-3.
Why it matters
Telesurgery is already expanding in China and India, and rapid advances in artificial intelligence, machine learning and connectivity are driving broader use of robotic systems in clinical settings. No remotely teleoperated or fully autonomous robotic device systems have received U.S. marketing authorization as of July, so the paper sets the stage for how such devices may be regulated.
The FDA's discussion paper is a request for public feedback rather than a regulatory decision, and no remotely teleoperated or fully autonomous robotic device systems have received U.S. marketing authorization as of July. Comments are due Jan. 5, and how these systems will be validated and regulated has not yet been determined.
The players
U.S. Food and Drug Administration (FDA)
The federal agency responsible for regulating medical devices in the United States, including robotic systems used in surgery and clinical care.
Dr. Vipul Patel
A surgeon who has performed robotic prostatectomies remotely, including a transatlantic procedure on a patient in Angola completed from Florida.
The details
The FDA is asking for feedback on the benefits and risks of robotic medical devices that have autonomous or remote teleoperation capabilities. In telesurgery, the surgeon operates from a console in a different location than the patient, and in October Dr. Vipul Patel performed a robotic prostatectomy about 35 miles away under an investigational device exemption.
Timeline
October: Dr. Vipul Patel performed a robotic prostatectomy about 35 miles from the patient.
Friday (Nov. 6, 2026): The FDA issued the discussion paper on robotic devices.
Dec. 2-3: A public workshop on topics raised in the paper is scheduled.
Jan. 5: The deadline for submitting comments on the discussion paper.
The Tech Race
Remote procedures like Patel's were performed under an investigational device exemption, which allows experimental devices to be used before marketing authorization. The FDA's discussion paper signals an effort to define how remote and autonomous robotic systems might eventually move beyond that investigational stage.
If remote and autonomous robotic systems are eventually authorized, patients in more locations could gain access to specialized surgical expertise without the surgeon traveling. The FDA's comment period gives clinicians, manufacturers and patients a formal channel to shape how those systems are evaluated before any approvals.
The takeaway
Remote and autonomous surgery is moving from isolated demonstrations toward a regulatory question, and the FDA's request for comments is the stage where that question is being framed. Readers interested in the outcome should watch the Jan. 5 comment deadline and the Dec. 2-3 workshop.
What happens next
Public comments on the FDA discussion paper are due Jan. 5, and a public workshop on the topics is scheduled for Dec. 2-3.
Further reading
For related coverage of how machines are entering the operating room, see Robotics.
Source note: This article includes information reported by MedTech Dive.
Live Poll
Would you trust a robot to perform surgery on you while the surgeon is far away?










